Introduction: Prostate cancer is the most non-cutaneous malignancy in men, and androgen-deprivation therapy (ADT) is a cornerstone of management in advanced disease. The aim of this study was to evaluate the association of ADT with changes in depression and mental and physical quality of life (QoL) within a prospective patient cohort design. Methods: Patients were prospectively recruited and consented at a single academic health sciences centre in Ontario, Canada. Inclusion criteria included those men with adenocarcinoma of the prostate and either on watchful waiting or initiating ADT as palliation or as an adjuvant therapy for high-risk localized disease. All three cohorts were followed in routine care and completed psychosocial evaluations, including depression, social support, anxiety, and QoL measures. Results: In comparison to the control cohort of patients with prostate cancer on watchful waiting, initiation of ADT over a two-year period of time was not associated with any changes in depression or mental QoL. Instead, all patients, regardless of treatment cohort, showed increased depression scores and reduced mental QoL scores over time; however, for patients receiving ADT, a significant reduction in physical QoL compared to patients who did not receive ADT was demonstrated. Conclusions: ADT does not appear to significantly impact depressive symptoms and mental QoL over a two-year period; however, the depressive symptoms in this limited sample of men with prostate cancer was higher than expected and monitoring for these may be advisable for those who care for such patients.
IntroductionProstate cancer is the most common non-cutaneous malignancy and the second leading cause of cancer-related death of men in North America.1 Androgen-deprivation therapy (ADT) remains a cornerstone of management of advanced disease; ADT improves survival when used in combination with radiotherapy in men with high-risk localized cancer, and represents standard palliation for men with incurable disease.2-4 Despite the cancer-related benefits, ADT has been well-shown to be associated with short-and long-term adverse effects, including sexual dysfunction, fatigue, hot flashes, osteoporosis, and cardiovascular complications.5 There is increasing evidence that ADT may also impact the psychological well-being of prostate cancer patients; 6,7 however, there are conflicting results in the literature as to the impact of ADT on depression. Many studies that have implicated ADT in depression either did not use validated depression-specific questionnaires or did not include control groups with patients suffering from prostate cancer and not receiving treatment. Thus, we sought to determine the impact of ADT on depression and mental and physical quality of life (QoL) in patients with both local and advanced disease using a prospective cohort study. We also wanted to determine the predictors of mental and physical QoL in men with prostate cancer.
Methods
ParticipantsParticipants were recruited from a single academic health sciences c...